AquaBounty Technologies, Inc. (NASDAQ:AQB) Short Interest Update

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 423,300 shares, a growth of 452.6% from the December 31st total of 76,600 shares. Based on an average trading volume of 425,500 shares, the short-interest ratio is currently 1.0 days. Approximately 11.7% of the shares of the company are sold short.

Hedge Funds Weigh In On AquaBounty Technologies

An institutional investor recently raised its position in AquaBounty Technologies stock. Epiq Partners LLC raised its holdings in AquaBounty Technologies, Inc. (NASDAQ:AQB) by 423.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 89,000 shares of the company’s stock after acquiring an additional 72,000 shares during the period. Epiq Partners LLC owned 2.30% of AquaBounty Technologies worth $56,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.92% of the company’s stock.

AquaBounty Technologies Trading Down 0.3 %

Shares of AquaBounty Technologies stock opened at $0.70 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.98 and a current ratio of 3.02. The firm has a fifty day moving average of $0.79 and a two-hundred day moving average of $1.06. AquaBounty Technologies has a one year low of $0.47 and a one year high of $2.79.

AquaBounty Technologies (NASDAQ:AQB) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.88) EPS for the quarter, meeting the consensus estimate of ($0.88). AquaBounty Technologies had a negative net margin of 5,842.69% and a negative return on equity of 18.20%. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.10 million. During the same quarter last year, the business earned ($1.60) earnings per share.

About AquaBounty Technologies

AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.